Bollinger Band Squeeze Stocks
ALLO appears in our Bollinger Band Squeeze Stocks screen. This means the stock is showing a tight volatility setup, where the Bollinger Bands have narrowed and price may be preparing for a larger breakout move.
ALLOGENE THERAPEUTICS INC (ALLO) Stock Price & Overview
NASDAQ:ALLO • US0197701065
Current stock price
2.39 USD
+0.07 (+3.02%)
At close:
2.38 USD
-0.01 (-0.42%)
Pre-Market:
The current stock price of ALLO is 2.39 USD. Today ALLO is up by 3.02%. In the past month the price increased by 8.14%. In the past year, price increased by 54.19%.
ALLO Key Statistics
52-Week Range0.8621 - 4.46
Current ALLO stock price positioned within its 52-week range.
1-Month Range1.85 - 4.46
Current ALLO stock price positioned within its 1-month range.
- Market Cap
- 582.634M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.87
- Dividend Yield
- N/A
ALLO Stock Performance
Today
+3.02%
1 Week
+10.14%
1 Month
+8.14%
3 Months
+38.95%
Longer-term
6 Months +99.17%
1 Year +54.19%
2 Years -13.41%
3 Years -55.99%
5 Years -92.27%
10 Years N/A
ALLO Stock Chart
ALLO Stock Screens
ALLO currently appears in the following ChartMill screener lists.
ALLO Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to ALLO. When comparing the yearly performance of all stocks, ALLO is one of the better performing stocks in the market, outperforming 88.93% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
ALLO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ALLO. While ALLO seems to be doing ok healthwise, there are quite some concerns on its profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
ALLO Earnings
Next Earnings DateMay 6, 2026
Last Earnings DateMar 12, 2026
PeriodQ4 / 2025
EPS Reported-$0.17
Revenue Reported
EPS Surprise 22.96%
Revenue Surprise %
ALLO Forecast & Estimates
21 analysts have analysed ALLO and the average price target is 7.57 USD. This implies a price increase of 216.59% is expected in the next year compared to the current price of 2.39.
Analysts
Analysts82.86
Price Target7.57 (216.74%)
EPS Next Y8.78%
Revenue Next YearN/A
ALLO Groups
Sector & Classification
ALLO Financial Highlights
Over the last trailing twelve months ALLO reported a non-GAAP Earnings per Share(EPS) of -0.87. The EPS increased by 34.59% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-190.89M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -45.9% | ||
| ROE | -65.25% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%39.29%
Sales Q2Q%N/A
EPS 1Y (TTM)34.59%
Revenue 1Y (TTM)-100%
ALLO Ownership
Ownership
Inst Owners48.61%
Shares243.78M
Float176.06M
Ins Owners6.2%
Short Float %18.21%
Short Ratio4.31
ALLO Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.52 | 354.636B | ||
| AMGN | AMGEN INC | 15.15 | 186.69B | ||
| GILD | GILEAD SCIENCES INC | 15.03 | 164.958B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.47 | 111.326B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.92 | 78.928B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.5 | 41.441B | ||
| INSM | INSMED INC | N/A | 31.186B | ||
| NTRA | NATERA INC | N/A | 29.449B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.041B | ||
| BIIB | BIOGEN INC | 11.79 | 27.895B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.65 | 25.171B | ||
| MRNA | MODERNA INC | N/A | 22.05B | ||
| INCY | INCYTE CORP | 12.5 | 19.252B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ALLO
Company Profile
Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is headquartered in South San Francisco, California and currently employs 150 full-time employees. The company went IPO on 2018-10-11. The firm is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. The company is focused on three core programs: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID), and Renal Cell Carcinoma (RCC). The company is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. The company is focused on developing cema-cel for LBCL. Its pipeline also includes ALLO-316 and ALLO-329.
Company Info
IPO: 2018-10-11
ALLOGENE THERAPEUTICS INC
210 East Grand Avenue
South San Francisco CALIFORNIA 94080 US
CEO: David Chang
Employees: 151
Phone: 16504572700
ALLOGENE THERAPEUTICS INC / ALLO FAQ
What does ALLO do?
Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is headquartered in South San Francisco, California and currently employs 150 full-time employees. The company went IPO on 2018-10-11. The firm is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. The company is focused on three core programs: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID), and Renal Cell Carcinoma (RCC). The company is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. The company is focused on developing cema-cel for LBCL. Its pipeline also includes ALLO-316 and ALLO-329.
What is the stock price of ALLOGENE THERAPEUTICS INC today?
The current stock price of ALLO is 2.39 USD. The price increased by 3.02% in the last trading session.
Does ALLOGENE THERAPEUTICS INC pay dividends?
ALLO does not pay a dividend.
What is the ChartMill technical and fundamental rating of ALLO stock?
ALLO has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the market cap for ALLOGENE THERAPEUTICS INC?
ALLOGENE THERAPEUTICS INC (ALLO) has a market capitalization of 582.63M USD. This makes ALLO a Small Cap stock.
What is the ownership structure of ALLOGENE THERAPEUTICS INC (ALLO)?
You can find the ownership structure of ALLOGENE THERAPEUTICS INC (ALLO) on the Ownership tab.
What is the Short Interest ratio of ALLOGENE THERAPEUTICS INC (ALLO) stock?
The outstanding short interest for ALLOGENE THERAPEUTICS INC (ALLO) is 18.21% of its float.